EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): UPDATED SAFETY ANALYSIS

被引：0
|
作者：
Nicolini, F. [1 ]
Alimena, G. [2 ]
Shen, Z. [3 ]
Al-Ali, H. -K [4 ]
Turkina, A. [5 ]
Smith, G. [6 ]
Pasquini, R. [7 ]
Jootar, S. [8 ]
Hsu, Y. [9 ]
Veronese, M. L. [9 ]
Powell, B. [10 ]
机构：
[1] Hop Edouard Herriot, Lyon, France
[2] Univ Roma La Sapienza, Rome, Italy
[3] Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Shanghai 200030, Peoples R China
[4] Univ Leipzig, Med Klin & Poliklin 2, Leipzig, Germany
[5] Hematol Sci Ctr, Moscow, Russia
[6] Leeds Teaching Hosp, Leeds, W Yorkshire, England
[7] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil
[8] Mahidol Univ, Salaya, Thailand
[9] Nova Pharmaceut Corp, E Hanover, NJ USA
[10] Wake Forest Univ, Baptist Med Ctr, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O134
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [41] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
    le Coutre, Philipp
    Bhalla, Kapil
    Giles, Francis
    Baccarani, Michele
    Ossenkoppele, Gert J.
    Hochhaus, Andreas
    Gattermann, Norbert
    Rafferty, Teresa
    Haque, Ariful
    Weitzman, Aaron
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [42] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [43] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [44] Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients (pts)treated with nilotinib: Lack of correlation between glucose levels and nilotinib efficacy.
    le Coutre, Philipp
    Giles, Francis J.
    Hochhaus, Andreas
    Martinelli, Giovanni
    Wang, Jim
    Passos, Vanessa
    Kayath, Marcia
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 219B - 219B
  • [45] BUDGET IMPACT ANALYSIS OF DASATINIB IN IMATINIB-RESISTANT OR-INTOLERANT PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) IN THE CHINESE SETTING
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
  • [46] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Activity and Tolerability of Nilotinib A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant
    Koren-Michowitz, Maya
    le Coutre, Philipp
    Duyster, Justus
    Scheid, Christof
    Panayiotidis, Panayiotis
    Prejzner, Witold
    Rowe, Jacob M.
    Schwarz, Michaela
    Goldschmidt, Neta
    Nagler, Arnon
    CANCER, 2010, 116 (19) : 4564 - 4572
  • [48] Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia
    Ionova, Tatyana I.
    Nikitina, Tatiana P.
    Gritsenko, Taras A.
    Ivanova, Valentina L.
    Kuchma, Galina B.
    Shnaider, Tatyana V.
    Fedorenko, Denis A.
    Kurbatova, Kira A.
    Novik, Andrei A.
    BLOOD, 2012, 120 (21)
  • [49] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    Giles, F. J.
    le Coutre, P. D.
    Pinilla-Ibarz, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Hochhaus, A.
    Radich, J. P.
    Saglio, G.
    Hughes, T. P.
    Martinelli, G.
    Kim, D-W
    Novick, S.
    Gillis, K.
    Fan, X.
    Cortes, J.
    Baccarani, M.
    Kantarjian, H. M.
    LEUKEMIA, 2013, 27 (01) : 107 - 112
  • [50] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    P D le Coutre
    J Pinilla-Ibarz
    R A Larson
    N Gattermann
    O G Ottmann
    A Hochhaus
    J P Radich
    G Saglio
    T P Hughes
    G Martinelli
    D-W Kim
    S Novick
    K Gillis
    X Fan
    J Cortes
    M Baccarani
    H M Kantarjian
    Leukemia, 2013, 27 : 107 - 112
12345